MARKET

GRFS

GRFS

Grifols S A
NASDAQ
6.27
-0.12
-1.88%
Closed 16:00 04/25 EDT
OPEN
6.33
PREV CLOSE
6.39
HIGH
6.37
LOW
6.12
VOLUME
1.01M
TURNOVER
0
52 WEEK HIGH
12.15
52 WEEK LOW
5.30
MARKET CAP
4.26B
P/E (TTM)
65.04
1D
5D
1M
3M
1Y
5Y
Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease
Benzinga · 3d ago
Weekly Report: what happened at GRFS last week (0415-0419)?
Weekly Report · 3d ago
Grifols SA’s Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns
Grifols SA (GRFS) has disclosed a new risk, in the Debt & Financing category. The company engages in transactions with related parties, which raises concerns about potential conflicts of interest. Wall Street has a Strong Buy consensus rating on GRFS stock based on 3 buys.
TipRanks · 4d ago
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Grifols celebrated the 50th anniversary of its flagship site in Clayton, N.C. Today. The company is a leading manufacturer of plasma-derived medicines. Grifols has saved the lives of millions of patients since its inception. The company's production of plasma has saved millions of lives.
Barchart · 04/18 08:30
Grifols reportedly looking to appoint independent directors
Spanish drugmaker Grifols reportedly looking to appoint independent directors. Short-seller Gotham Research accused the company of accounting irregularities in January. The company has been criticized for its accounting practices. Grifol's CEO says appointing independent directors will help improve the company's governance.
Seeking Alpha · 04/15 15:37
Weekly Report: what happened at GRFS last week (0408-0412)?
Weekly Report · 04/15 09:24
ATUS, ATHE and GRFS among pre-market losers
On the Move ATUS, ATHE and GRFS among pre-market losers. Aptevo Therapeutics (APVO) -55% on pricing public offering. Carmax (KMX) -9% after Q4 earnings release. Altice USA, Inc. (ATUS) and Grifols SA (GRFS) in the red.
Seeking Alpha · 04/11 12:16
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Shares of CarMax, Inc. Fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax shares dipped 9.1% to $72.06 in pre- market trading. The Lovesac Company shares fell 13% after reporting worse- than-expected results. The Dow futures fell over 150 points on Thursday.
Benzinga · 04/11 12:03
More
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers Grifols SA - ADR stock information, including NASDAQ: GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.